Senior Director, Business Development at evitria
Mail: rp@evitria.com
Starting at evitria in 2020 as Director of Client Relations, Richard Park has been Senior Director, Business Development at Evitria since 2024. This makes him the interface between clients and the company, specialized in providing service solutions for expression and purification in the antibody production.
Richard Park graduated from Brown University with Bachelor’s degrees in French studies and biomedical engineering, the latter of which he concluded with a thesis on the “Dilutive effects of protein-SDS complexes in microfluidic gel electrophoresis”. Consequently, he has gained broad experience in the biotechnology industry as well as being concerned with civil rights and social actions.
LinkedIn profile: Richard Park
Articles
At evitria, we are specialized in transient transfection of CHO cells to produce recombinant antibodies. Find out more about our approach in this article.
Both transient and stable transfection are essential methods in genetic engineering. But what are the differences between them? Let’s find out in this article.
Transient transfection offers numerous advantages in the expression of recombinant proteins. We will uncover the main benefits in this article.